GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arena Pharmaceuticals Inc (FRA:RN3N) » Definitions » Cyclically Adjusted PS Ratio

Arena Pharmaceuticals (FRA:RN3N) Cyclically Adjusted PS Ratio : (As of May. 21, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Arena Pharmaceuticals Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Arena Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Arena Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arena Pharmaceuticals Cyclically Adjusted PS Ratio Chart

Arena Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Arena Pharmaceuticals Quarterly Data
Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Arena Pharmaceuticals's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Arena Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arena Pharmaceuticals's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arena Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Arena Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.



Arena Pharmaceuticals Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Arena Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2021 is calculated as:

For example, Arena Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Dec. 2021 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2021 (Change)*Current CPI (Dec. 2021)
=0.001/117.6295*117.6295
=0.001

Current CPI (Dec. 2021) = 117.6295.

Arena Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201203 0.101 96.783 0.123
201206 0.921 96.819 1.119
201209 0.054 97.633 0.065
201212 0.068 96.871 0.083
201303 0.084 98.209 0.101
201306 2.327 98.518 2.778
201309 0.123 98.790 0.146
201312 0.218 98.326 0.261
201403 0.225 99.695 0.265
201406 0.418 100.560 0.489
201409 0.288 100.428 0.337
201412 0.339 99.070 0.403
201503 0.480 99.621 0.567
201506 0.338 100.684 0.395
201509 0.336 100.392 0.394
201512 -0.650 99.792 -0.766
201603 0.364 100.470 0.426
201606 0.348 101.688 0.403
201609 0.705 101.861 0.814
201612 2.087 101.863 2.410
201703 0.063 102.862 0.072
201706 0.056 103.349 0.064
201709 0.054 104.136 0.061
201712 0.466 104.011 0.527
201803 0.036 105.290 0.040
201806 0.069 106.317 0.076
201809 0.062 106.507 0.068
201812 0.154 105.998 0.171
201903 13.832 107.251 15.171
201906 0.018 108.070 0.020
201909 0.025 108.329 0.027
201912 0.052 108.420 0.056
202003 0.005 108.902 0.005
202006 0.000 108.767 0.000
202009 0.000 109.815 0.000
202012 0.001 109.897 0.001
202103 0.000 111.754 0.000
202106 0.000 114.631 0.000
202109 0.000 115.734 0.000
202112 0.001 117.630 0.001

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Arena Pharmaceuticals  (FRA:RN3N) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Arena Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Arena Pharmaceuticals's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Arena Pharmaceuticals (FRA:RN3N) Business Description

Traded in Other Exchanges
N/A
Address
136 Heber Avenue, Suite 204, Park City, UT, USA, 84060
Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company's pipeline contains drugs targeting autoimmune diseases, vascular diseases, thrombotic diseases, dementia-associated psychosis, nervous system issues, and pain.

Arena Pharmaceuticals (FRA:RN3N) Headlines

No Headlines